Astrea Bioseparations (“Astrea Bio”), a leading provider of high-quality bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics, announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.
Acadia snaps up an essential tremor drug after field’s summer setbacks
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
November 28, 2024